c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 143 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
c-Kit-IN-1
CAS:c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).Fórmula:C26H21F2N5O3Pureza:98.72% - 98.73%Cor e Forma:SolidPeso molecular:489.47Ref: TM-T4332
1mg39,00€5mg81,00€10mg120,00€25mg235,00€50mg373,00€100mg610,00€200mg840,00€1mL*10mM (DMSO)88,00€X-376
CAS:X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.Fórmula:C25H25Cl2FN6O3Pureza:97.87%Cor e Forma:SolidPeso molecular:547.41Ref: TM-T3550
1mg35,00€2mg50,00€5mg87,00€10mg119,00€25mg258,00€50mg427,00€100mg582,00€1mL*10mM (DMSO)105,00€BMS817378
CAS:BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).Fórmula:C24H18ClF2N4O7PPureza:>99.99%Cor e Forma:SolidPeso molecular:578.85Ensartinib hydrochloride
CAS:Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFórmula:C26H29Cl4FN6O3Pureza:98.73%Cor e Forma:SolidPeso molecular:634.36Ref: TM-T22324
1mg54,00€5mg114,00€10mg177,00€25mg356,00€50mg580,00€100mg888,00€1mL*10mM (DMSO)158,00€Glumetinib
CAS:Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).
Fórmula:C21H17N9O2SPureza:99.79%Cor e Forma:SolidPeso molecular:459.48Hepln-13
CAS:Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Fórmula:C17H13BrN2Pureza:97.67%Cor e Forma:SolidPeso molecular:325.2Ref: TM-T25492
1mg35,00€2mg52,00€5mg80,00€10mg119,00€25mg231,00€50mg344,00€100mg480,00€200mg663,00€1mL*10mM (DMSO)92,00€Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Cor e Forma:SolidPeso molecular:510.46NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Fórmula:C20H16N6Pureza:97.24% - >99.99%Cor e Forma:SolidPeso molecular:340.38Ref: TM-T2680
2mg44,00€5mg74,00€10mg97,00€25mg178,00€50mg255,00€100mg359,00€200mg510,00€1mL*10mM (DMSO)84,00€BMS 777607
CAS:BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Fórmula:C25H19ClF2N4O4Pureza:98.89% - >99.99%Cor e Forma:SolidPeso molecular:512.89Ref: TM-T2699
1mg35,00€5mg79,00€10mg124,00€25mg217,00€50mg359,00€100mg533,00€500mg1.169,00€1mL*10mM (DMSO)92,00€MK-8033
CAS:MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Fórmula:C25H21N5O3SPureza:97.16%Cor e Forma:SolidPeso molecular:471.53Golvatinib
CAS:Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFórmula:C33H37F2N7O4Pureza:98.24% - ≥95%Cor e Forma:SolidPeso molecular:633.69Ref: TM-T6517
1mgA consultar2mg46,00€5mg66,00€10mg92,00€25mg149,00€50mg197,00€100mg350,00€1mL*10mM (DMSO)A consultarAMG-337
CAS:AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Fórmula:C23H22FN7O3Pureza:99.26% - 99.9%Cor e Forma:SolidPeso molecular:463.46Ref: TM-T3209
1mg40,00€2mg52,00€5mg85,00€10mg124,00€25mg197,00€50mg350,00€100mg522,00€200mg748,00€1mL*10mM (DMSO)86,00€Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H21Cl2FN6O2Pureza:99.77%Cor e Forma:SolidPeso molecular:503.36Ref: TM-T8825
2mg34,00€5mg48,00€10mg63,00€25mg84,00€50mg92,00€100mg126,00€500mg250,00€1mL*10mM (DMSO)50,00€Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Cor e Forma:SolidPeso molecular:632.65Ref: TM-T3113
2mg39,00€5mg57,00€10mg79,00€25mg133,00€50mg207,00€100mg354,00€500mg848,00€1mL*10mM (DMSO)79,00€Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Fórmula:C31H29FN4O5Pureza:99.95% - 99.98%Cor e Forma:SolidPeso molecular:556.58Afatinib
CAS:Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.
Fórmula:C24H25ClFN5O3Pureza:98.56% - 99.9%Cor e Forma:Off-White SolidPeso molecular:485.94BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFórmula:C17H15N5Pureza:98.98%Cor e Forma:SolidPeso molecular:289.33Ref: TM-T7900
1mg35,00€5mg71,00€10mg112,00€25mg203,00€50mg294,00€100mg411,00€200mg553,00€1mL*10mM (DMSO)84,00€Crizotinib hydrochloride
CAS:Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)Fórmula:C21H23Cl3FN5OPureza:98.73% - 98.87%Cor e Forma:SolidPeso molecular:486.8Ref: TM-T8399
5mg34,00€10mg50,00€25mg78,00€50mg94,00€100mg131,00€200mg162,00€500mg215,00€1mL*10mM (DMSO)56,00€Cabozantinib hydrochloride
CAS:Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Fórmula:C28H25ClFN3O5Pureza:99.97%Cor e Forma:SolidPeso molecular:537.96Ref: TM-T5164
1mg42,00€2mg52,00€5mg65,00€10mg92,00€25mg160,00€50mg235,00€100mg330,00€200mg538,00€500mg860,00€(Z)-Semaxinib
CAS:(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFórmula:C15H14N2OPureza:98.82% - ≥95%Cor e Forma:SolidPeso molecular:238.28Ref: TM-T2496
10mg35,00€25mg52,00€50mg79,00€100mg111,00€200mg168,00€500mg330,00€1mL*10mM (DMSO)44,00€Cabozantinib
CAS:Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).
Fórmula:C28H24FN3O5Pureza:99.68% - 99.88%Cor e Forma:SolidPeso molecular:501.51SRI 31215 TFA
CAS:SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Fórmula:C27H34F3N5O3Pureza:98.25% - 99.97%Cor e Forma:SolidPeso molecular:533.6Ref: TM-T5478
1mg40,00€5mg92,00€10mg128,00€25mg248,00€50mg370,00€100mg527,00€200mg713,00€1mL*10mM (DMSO)96,00€Capmatinib xHCl
CAS:Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Fórmula:C23H18ClFN6OPureza:98.62% - 99.81%Cor e Forma:SolidPeso molecular:448.89Merestinib dihydrochloride
CAS:Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.Fórmula:C30H24Cl2F2N6O3Cor e Forma:SolidPeso molecular:625.45Savolitinib
CAS:Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Fórmula:C17H15N9Pureza:98.12%Cor e Forma:SolidPeso molecular:345.36Ref: TM-TQ0210
1mg47,00€2mg60,00€5mg96,00€10mg124,00€25mg200,00€50mg353,00€100mg537,00€1mL*10mM (DMSO)92,00€MGCD-265 analog
CAS:Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Fórmula:C26H20FN5O2S2Pureza:98.06% - 98.68%Cor e Forma:SolidPeso molecular:517.6Ref: TM-T6351
2mg35,00€5mg52,00€10mg85,00€25mg164,00€50mg255,00€100mgA consultar1mL*10mM (DMSO)62,00€Merestinib
CAS:Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.Fórmula:C30H22F2N6O3Pureza:95% - 99.71%Cor e Forma:SolidPeso molecular:552.53Ref: TM-T3455
1mg50,00€2mg66,00€5mg100,00€10mg137,00€25mg240,00€50mg403,00€100mg573,00€500mg1.198,00€1mL*10mM (DMSO)119,00€Tivantinib
CAS:Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Fórmula:C23H19N3O2Pureza:98% - 99.41%Cor e Forma:SolidPeso molecular:369.42RPI-1
CAS:RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.Fórmula:C17H15NO4Pureza:98.91% - ≥95%Cor e Forma:SolidPeso molecular:297.31SGI-7079
CAS:SGI-7079: selective Axl inhibitor; hinders tumor growth dose-dependently; may target EGFR inhibitor resistance.Fórmula:C26H26FN7Pureza:95.51% - 99.26%Cor e Forma:SolidPeso molecular:455.53Ref: TM-T6982
2mg39,00€5mg58,00€10mg92,00€25mg178,00€50mg230,00€100mg334,00€500mg782,00€1mL*10mM (DMSO)64,00€JNJ-38877605
CAS:JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Fórmula:C19H13F2N7Pureza:97.15% - 98.61%Cor e Forma:SolidPeso molecular:377.35BMS-2
CAS:BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Fórmula:C25H16F2N4O3Pureza:98.33%Cor e Forma:SolidPeso molecular:458.42Ref: TM-T8326
1mg67,00€2mg88,00€5mg148,00€10mg230,00€25mg430,00€50mg622,00€100mg898,00€1mL*10mM (DMSO)170,00€XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Fórmula:C29H25FN4O5Pureza:98.60%Cor e Forma:SolidPeso molecular:528.53SCR-1481B1
CAS:SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFórmula:C32H40ClF2N6O13PPureza:98.07%Cor e Forma:SolidPeso molecular:821.12Ref: TM-T5349
1mg35,00€2mg50,00€5mg74,00€10mg113,00€25mg200,00€50mg333,00€100mg495,00€1mL*10mM (DMSO)102,00€Pamufetinib mesylate
CAS:Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Fórmula:C28H27FN4O7S2Pureza:98.91%Cor e Forma:SolidPeso molecular:614.67Foretinib phosphate
CAS:Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Fórmula:C34H40F2N4O14P2Cor e Forma:SolidPeso molecular:828.65Amivantamab (Anti-c-MET)
CAS:Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.Pureza:97.24% (SEC-HPLC) - >95.0% (SDS-PAGE); 99.74% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:145.88 kDaDavutamig
CAS:Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Pureza:98%Cor e Forma:LiquidBafisontamab
CAS:Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].Cor e Forma:LiquidMAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFórmula:C20H11Cl2N3OPureza:98%Cor e Forma:SolidPeso molecular:380.23BMS-754807
CAS:BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.Fórmula:C23H24FN9OPureza:99.69% - 99.94%Cor e Forma:SolidPeso molecular:461.49Ref: TM-T2349
1mg50,00€2mg66,00€5mg90,00€10mg158,00€25mg310,00€50mg509,00€100mg732,00€1mL*10mM (DMSO)110,00€SU11274
CAS:SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Fórmula:C28H30ClN5O4SPureza:98.62% - 99.53%Cor e Forma:Orange PowderPeso molecular:568.09Ref: TM-T6154
1mg44,00€2mg56,00€5mg92,00€10mg142,00€25mg268,00€50mg442,00€100mg652,00€1mL*10mM (DMSO)142,00€AMG-458
CAS:AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Fórmula:C30H29N5O5Pureza:99.91% - 99.98%Cor e Forma:SolidPeso molecular:539.58Glesatinib hydrochloride
CAS:Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H28ClF2N5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:656.16Glesatinib
CAS:Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H27F2N5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:619.7AC-386
CAS:AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.Fórmula:C35H34FN5O6Cor e Forma:SolidPeso molecular:639.67LCRF-0004
CAS:LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.Fórmula:C28H18F4N6O2SCor e Forma:SolidPeso molecular:578.54c-Met-IN-11
CAS:c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).Fórmula:C30H20F2N4O3Cor e Forma:SolidPeso molecular:522.5Axl-IN-8
CAS:Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).Fórmula:C31H29FN6O3Cor e Forma:SolidPeso molecular:552.6Mifanertinib
CAS:Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Fórmula:C21H19ClF3N5O2Cor e Forma:SolidPeso molecular:465.86
